How I do It: Autologous Bone Marrow Cell Delivery at Surgical Repair of Ebstein Anomaly
Kimberly Holst, MD, Joseph Dearani, MD, M. Yasir Qureshi, MBBS, Patrick O'Leary, MD, Bryan Cannon, MD, Philip Wackel, MD, Timothy Olson, MD, Timothy Nelson, MD, PhD.
Mayo Clinic, Rochester, MN, USA.
Current surgical therapies for Ebstein anomaly (EA) are unable to address the underlying right ventricular myopathy inherent to the disease. We have designed a phase I clinical trial utilizing autologous bone marrow derived mononuclear cells (BM-MNC) administered at the time of elective surgical repair in patients with EA in attempt to re-engineer cellular and physiologic features within the native right ventricle. This video will highlight an overview of the clinical trial, intramyocardial cell delivery following Cone repair, and early outcomes.
Back to 2018 Program
